Year: 2025
Type: article
Abstract: Immune checkpoint inhibitors (ICIs), which target the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), programmed death-1 (PD-1), programmed death–ligand-1 (PD-L1), and lymphocyte activation gene-3 (LAG-3) pathways, have revolutionized cancer treatment. In 2011, the Food and Drug Administration (FDA) approved ipilimumab (the first ICI) for the treatment of advanced melanoma. Since then, the number of approved ICIs and their indications have increased exponentially, demonstrating the extraordinary potential of these drugs in treating various tumors. Currently, 11 ICIs are approved for nearly 20 types of cancer, including melanoma, lung cancer, renal cell carcinoma, and endometrial cancer, with indications continuing to expand over time.[1]
Author: Pirovano, M.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7082112812
